COMP <GO>
TARS vs IOVA // 10Y YIELD & FRED MACRO BETA
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Iovance Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TARS 8
— IOVA 1
■ METRIC PARITY
LAST: $72.64 (-0.93%) • MKT CAP: $3.61B
macro-sensitivity
—
LAST: $8.83 (+10.10%) • MKT CAP: $3.63B
macro-sensitivity
0.99
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. IOVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | IOVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 34.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | -35.00% | +10.90 | TARS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | -7.76% | +7.15 | TARS | /fcf-yield <GO> |
| Operating Margin | -15.70% | -60.00% | +44.30 | TARS | /operating-margins <GO> |
| Net Profit Margin | -14.60% | -60.00% | +45.40 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) | 146.70% | 60.60% | +86.10 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | 7.08 | +3.11 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | TARS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.9 | 31.8 | +19.10 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.99 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 33.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.61B | $3.63B | -$17.9M | IOVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | IOVA REV | TARS GROSS % | IOVA GROSS % | TARS FCF | IOVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $263.5M | — | 34.3% | -$22.3M | -$336.2M |
| FY 2024 | $183.0M | $164.1M | — | 43.2% | -$84.6M | -$364.0M |
| FY 2023 | $17.4M | $1.2M | — | — | -$117.5M | -$361.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
IOVA // BETA 0.99